Serum Cortistatin Levels in Patients with Ocular Active and Ocular Inactive Behçet Disease

REFERENCES

• Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, et al. Etiopathogenesis of Behçet’s disease. Autoimmun Rev. 2010;9(4):241–245. doi:10.1016/j.autrev.2009.10.005.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Kikuchi H. Behçet’s disease. Arthritis Res Ther. 2003;5:139–146.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med. 2014;9(3):257–265. doi:10.1007/s11739-013-1036-5.
   PubMed Web of Science ®Google Scholar
• Spier AD, de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Rev. 2000;33(2–3):228–241.
   PubMedGoogle Scholar
• de Lecea L, Criado JR, Prospero-Garcia O, et al. A cortical neuropeptide with neuronal depressant and sleep modulating properties. Nature. 1996;381(6579):242–245. doi:10.1038/381242a0.
   PubMed Web of Science ®Google Scholar
• Dalm VA, Van Hagen PM, Van Koetsveld PM, et al. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatine receptors in the humane immune system. J Clin Endocrinol Metab. 2003;88(1):270–276. doi:10.1210/jc.2002-020950.
   PubMed Web of Science ®Google Scholar
• Delgado M, Ganea D. Anti-inflammatory neuropeptıdes: A new class of endogenous immunoregulatory agents. Brain Behav Immune. 2008;22(8):1146–1151. doi:10.1016/j.bbi.2008.06.001.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB. Behçet’s Disease. In: Nussenblatt RB, Whitcup SM, eds. Uveitis: Fundamentals and Clinical Practice. 4th ed. St. Louis, MO: Mosby; 2010:332–354.
   Google Scholar
• Meesquida M, Molins B, Llorenç V, et al. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet’s disease. Mediators Inflamm. 2014;2014:396204. doi:10.1155/2014/396204.
   PubMed Web of Science ®Google Scholar
• Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet’s disease: which and when to use. Clin Rheumatol. 2018;37(10):2811–2817. doi:10.1007/s10067-018-4194-z.
   PubMed Web of Science ®Google Scholar
• Balkarlı A, Küçük A, Babur H, Erbasan F. Neutrophil/lymphocyte ratio and mean platelet volüme in Behçet’s disease. Eur Rev Med Pharmacol Sci. 2016;20(14):3045–3050.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Murata H, Takamoto M, et al. Behçet’s disease ocular attack score 24 and visual outcome in patients with Behçet’s disease. Br J Ophthalmol.2016. 100(7):990–994.
   PubMed Web of Science ®Google Scholar
• International Team fort he revision of the International criteria for Behçet’s disease (ITR-ICBD). The International Criteria for Behçet’s disease (ICBD): a collaborative study of 27 countries on sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–347. doi:10.1111/jdv.12107.
   PubMed Web of Science ®Google Scholar
• Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet’s disease activity index. Rheumatology (Oxford). 2004;43(1):73–78. doi:10.1093/rheumatology/keg453.
   PubMed Web of Science ®Google Scholar
• Pay S, Simsek I, Erdem H, Dinc A. Immunopathogenesis of Behcet’s disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int. 2007;27(5):417–424. doi:10.1007/s00296-006-0281-6.
   PubMed Web of Science ®Google Scholar
• Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behcet‘s disease. J Invest Dermatol. 2010;130(8):2136–2138. doi:10.1038/jid.2010.114.
   PubMed Web of Science ®Google Scholar
• Pinter E, Pozsgai G, Hajna Z, Helyes Z, Szolcsanyi J. Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions. Br J Clin Pharmacol. 2014;77(1):5–20. doi:10.1111/bcp.12097.
   PubMed Web of Science ®Google Scholar
• Dalm VA. Expression of somatostatin, cortistatin and somatostatin receptors in human monocytes, macrophages and dentritic cells. Am J Physiol Endocrinol Metabol. 2003;285(2):344–353. doi:10.1152/ajpendo.00048.2003.
   PubMed Web of Science ®Google Scholar
• Krantic S. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides. 2000;21:1941–1964.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Varela N, Sheibanie F, Chorny A, Ganea M, Delgado M. Cortistatin, an inflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci USA. 2006;103(11):4228–4233. doi:10.1073/pnas.0508997103.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Chorny A, Robledo G, et al. Cortistatin, a new anti-inflammatory peptide with therapeutic action in lethal endotoxemia. J Exp Med. 2006;203(3):563–571. doi:10.1084/jem.20052017.
   PubMed Web of Science ®Google Scholar
• Delgado- Marato V, Benitez R, Forte-Lago I, et al. Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells. Sci Rep. 2017;13(7):46444. doi:10.1038/srep46444.
   Google Scholar
• Gonzalez-Rey E, Pedreno M, Delgado-Maroto V, Souza-Moreira L, Delgado M. Lulling immunity, pain and stress to sleep with cortistatin. Ann. N.Y. Acad. Sci. 2015;1351:89–98. doi:10.1111/nyas.12789.
   PubMed Web of Science ®Google Scholar
• Zhang B, Sun GZ, Zhu ML, Li Y, Sun DJ, Bai XP. The plasma levels of CST and BCKDK in patients with sepsis. Peptides. 2016;86:80–84. doi:10.1016/j.peptides.2016.10.006.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Chorny A, Del Moral RG, Varela N, Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis. 2007;66(5):582–588. doi:10.1136/ard.2006.062703.
   PubMed Web of Science ®Google Scholar